Skip to content
BY 4.0 license Open Access Published by De Gruyter March 8, 2022

Reply to: Spurious results for total and free prostate-specific antigen (PSA); sometimes really “a riddle wrapped in a mystery inside an enigma”

Simona Ferraro, Elia Mario Biganzoli and Mario Plebani ORCID logo

To the Editor,

Dorizzi et al. [1] reported a relevant clinical case on the aberrant free/total prostate specific antigen (fPSA/tPSA) percentages increasing over 100% and on the discrepant results of tPSA and fPSA obtained from different assays. We agree with the authors that these cases should be deeply investigated and reported in literature since actually uncommon. We should remind that in these rare cases the measurement of the biomarkers results in an unfavourable risk-benefit and cost-effectiveness ratio for the patient and the healthcare systems respectively. Indeed, as described in this case, more investigations (i.e. biopsy, magnetic resonance imaging, additional PSA measurements…) are required to try to explain the aberrant fPSA/tPSA ratios which cause a further increase of the health care costs and worsen the quality of life of the patient [2]. The interplay between laboratory professionals (as described in this case), urologists and manufacturers is therefore needed to increase the knowledge, share the evidence and finally improve the technology. We should remind that these efforts are made in order to restore the benefit of biomarker evaluation on healthcare and patient. In our opinion the stewardship of laboratory professionals is not affected by the lack of indication of the immunoassay used for PSA testing in the laboratory report but by the lack of knowledge on the state of harmonization of PSA immunoassays and the lack of a clinical-laboratory interface [2, 3]. The state of harmonization is undoubtedly suboptimal for tPSA methods (inter-assay coefficient of variation (CV)=11.5%) but really poor for fPSA (inter-assay CV=20.4%) methods, considering however that these results have been generated in a screening context characterized by a lowest risk of having aberrant results as those reported in this case [4, 5]. We will cautionary consider the cross-reactivity with human kallikrein (hK2) of Roche assay as possible explanation of these aberrant results between Beckman and Roche immunoassays, as reported by Dorizzi et al. [1], since a relevant (and possibly interfering) increase of hK2 may be detected in patients with high grade tumors and this is not the case [6, 7]. We encourage the use of other technologies (i.e. mass spectrometry) as an aid to investigate the presence of isoforms that may be recognized by fPSA immunoassays and cause spurious increases [8]. In conclusion, this case report [1] may be considered a good example of laboratory stewardship further encouraging to invest on more research towards fPSA and tPSA assay harmonization. It reminds that post-market assessments are needed for improving the cost-effectiveness of laboratory testing and practice.


Corresponding author: Simona Ferraro, UOSD di Endocrinologia, ASST Fatebenefratelli-Sacco, Ospedale ‘Luigi Sacco’, Via GB Grassi 74, Milan, 20157, Italy; and Endocrinology Laboratory Unit, “Luigi Sacco” University Hospital, Milan, Italy, E-mail:

  1. Research funding: None declared.

  2. Author contribution: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable.

References

1. Dorizzi, RM, Maltoni, P, Sgarzani, C, Torello, M, Montanari, F. Spurious results for total and free prostate-specific antigen (PSA); sometimes really “a riddle wrapped in a mystery inside an enigma”. Clin Chem Lab Med 2022;60:e91–4.10.1515/cclm-2022-0036Search in Google Scholar

2. Plebani, M, Panteghini, M. Promoting clinical and laboratory interaction by harmonization. Clin Chim Acta 2014;432:15–21, https://doi.org/10.1016/j.cca.2013.09.051.Search in Google Scholar

3. Ferraro, S, Braga, F, Panteghini, M. Laboratory medicine in the new healthcare environment. Clin Chem Lab Med 2016;54:523–33, https://doi.org/10.1515/cclm-2015-0803.Search in Google Scholar

4. Ferraro, S, Bussetti, M, Rizzardi, S, Braga, F, Panteghini, M. Verification of harmonization of serum total and free prostate-specific antigen (PSA) measurements and implications for medical decisions. Clin Chem 2021;67:543–53, https://doi.org/10.1093/clinchem/hvaa268.Search in Google Scholar

5. Ferraro, S, Biganzoli, EM. The clinical value of assessing the inter-method bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med 2021;60:149–51, https://doi.org/10.1515/cclm-2021-1125.Search in Google Scholar

6. Ferraro, S, Bussetti, M, Panteghini, M. Serum prostate specific antigen (PSA) testing for early detection of prostate cancer: managing the gap between clinical and laboratory practice. Clin Chem 2021;67:602–9, https://doi.org/10.1093/clinchem/hvab002.Search in Google Scholar

7. Recker, F, Kwiatkowski, MK, Piironen, T, Pettersson, K, Huber, A, G Lümmen, et al.. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000;55:481–5, https://doi.org/10.1016/s0090-4295(99)00611-1.Search in Google Scholar

8. Klee, EW, Bondar, OP, Goodmanson, MK, Trushin, SA, Singh, RJ, Anderson, NL, et al.. Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences. Am J Clin Pathol 2014;141:527–33, https://doi.org/10.1309/ajcp8pel0yxahdvk.Search in Google Scholar

Received: 2022-02-02
Accepted: 2022-02-03
Published Online: 2022-03-08
Published in Print: 2022-04-26

© 2022 Simona Ferraro et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.